NASDAQ:TRIB opened at $1.15 on Friday. The stock has a market cap of $24.04 million, a price-to-earnings ratio of 12.78 and a beta of 1.33. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.37. Trinity Biotech has a 52 week low of $0.86 and a 52 week high of $3.98.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last issued its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.13). Trinity Biotech had a net margin of 0.94% and a negative return on equity of 27,745.46%.
Trinity Biotech Company Profile (Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.